The Lung Cancer Alliance (LCA) has applauded the USFDA on its recent approval of Avastin (bevacizumab) for the most common type of lung cancer.
Laurie Fenton, President of Lung Cancer Alliance in Washington, D.C. stated:
“Lung cancer is responsible for over one-third of all U.S. cancer deaths, killing more people than breast, prostate, colon, liver and kidney cancers combined each year.
Sadly, we have few arrows in our treatment quiver to address this lethal killer. That is why the ability to use Avastin as a treatment method, along with chemotherapy, is a significant development for the lung cancer community.”

Manufactured by Genentech, Inc. (NYSE: DNA), …read more